Lixte Biotechnology Holdings Inc
Company Profile
Business description
Lixte Biotechnology Holdings Inc is a biopharmaceutical company dedicated to improving patients' lives by developing a drug class called Protein Phosphatase 2A inhibitors. Its product pipeline is focused on inhibitors of protein phosphatase 2A, used in combination with cytotoxic agents and/or x-rays, immune checkpoint blockers, and other cancer therapies. The Company believes that inhibitors of protein phosphatases have therapeutic potential for a broad range of cancers. It focuses on the clinical development of a specific protein phosphatase inhibitor, referred to as LB-100, which has been shown to have clinical anti-cancer activity at doses that produce little or no toxicity.
Contact
680 East Colorado Boulevard
Suite 180
PasadenaCA91101
USAT: +1 631 830-7092
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
4
Stocks News & Analysis
stocks
Chart of the Week: The market may be underestimating Amcor’s long term potential
stocks
Competitive pressures highlight need to lower costs for big 4 bank
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,034.50 | 50.40 | -0.55% |
| CAC 40 | 8,270.28 | 29.04 | 0.35% |
| DAX 40 | 24,232.41 | 149.05 | -0.61% |
| Dow JONES (US) | 48,254.82 | 326.86 | 0.68% |
| FTSE 100 | 9,844.06 | 67.36 | -0.68% |
| HKSE | 27,073.03 | 150.30 | 0.56% |
| NASDAQ | 23,406.46 | 61.84 | -0.26% |
| Nikkei 225 | 51,281.83 | 218.52 | 0.43% |
| NZX 50 Index | 13,597.87 | 73.86 | -0.54% |
| S&P 500 | 6,850.92 | 0.00 | 0.00% |
| S&P/ASX 200 | 8,753.40 | 46.00 | -0.52% |
| SSE Composite Index | 4,029.50 | 29.36 | 0.73% |